Previously recorded as Gemphire Therapeutics Inc. (to 2020)
Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2032
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2014 to 2040.
US 10,227,285
Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers
Nov 16, 2035
US 10,864,238
Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders
Dec 3, 2035
US 10,946,053
Composition Containing Mixed Extract of Mulberry and Poria Cocos Bark for Preventing, Improving or Treating Neurodegenerative Disorders
Dec 3, 2035
US 12,503,422
Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor
Oct 30, 2040
201920242029203420392040
1 pending application: term is not computable until grant.Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2036 · Medium confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends Jan 2033 · High confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends Oct 2040 · High confidence
Treatment of NASH with Gemcabene
US 9,849,104
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2036.
Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel
US 10,588,927
Granted 2020. Computed term ends 2036.
Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers
US 10,227,285
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders
US 10,864,238
Granted 2020. Computed term ends 2035. A terminal disclaimer caps this term to an earlier patent's.
Methods of Reducing Risk of Cardiovascular Disease
US 10,709,678
Granted 2020. Computed term ends 2033.
Method for Treating Pancreatitis
US 8,846,761
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2032.
Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor
US 12,503,422
Granted 2025. Too new for citation comparison; protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 22, 2027The maintenance fee for Treatment of NASH with Gemcabene (US 10,449,154) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel (US 10,588,927) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Treatment of NASH with Gemcabene | 2 in force | to Nov 2036 |
| Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel | 2 in force | to Jan 2036 |
| Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor | 1 in force | to Oct 2040 |
| Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders | 1 in force | to Dec 2035 |
| Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers | 1 in force | to Nov 2035 |
| Methods of Reducing Risk of Cardiovascular Disease | 1 in force | to Jan 2033 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,846,761 | Method for Treating Pancreatitis In force · High confidence | In force | High confidence | |
| US 10,709,678 | Methods of Reducing Risk of Cardiovascular Disease In force · High confidence | In force | High confidence | |
| US 10,227,285 | Processes and Intermediates for Preparing Alpha,omega -Dicarboxylic Acid-Terminated Dialkane Ethers In force · High confidence | In force | High confidence | |
| US 10,864,238 | Composition Containing Poria Cocos Peel Extract for Treating Neurodegenerative Disorders In force · High confidence | In force | High confidence | |
| US 10,946,053 | Composition Containing Mixed Extract of Mulberry and Poria Cocos Bark for Preventing, Improving or Treating Neurodegenerative Disorders In force · High confidence | In force | High confidence | |
| US 10,588,927 | Composition Containing Mixed Extract of Mulberry and Poria Cocos Peel In force · High confidence | In force | High confidence | |
| US 9,849,104 | Treatment of NASH with Gemcabene In force · Medium confidence | In force | Medium confidence | |
| US 10,449,154 | Treatment of NASH with Gemcabene In force · Medium confidence | In force | Medium confidence | |
| US 12,503,422 | Gemcabene, Pharmaceutically Acceptable Salts Thereof, Compositions Thereof and Methods of Use Therefor In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 patent ended · 1 application pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.